Untargeted metabolomics holds the power to reveal thousands of molecular signals, offering an unprecedented view of biology. Panome Bio elevated this potential with Next-Generation Metabolomics® and now sets an even higher standard of confidence and rigor with MassID.
MassID is Panome Bio’s identification engine for Next-Generation Metabolomics, designed to evaluate complex LC/MS data against a reference database of more than 280,000 compounds and produce reproducible, high-confidence metabolite profiles.
More Metabolites. More Pathways.
The Challenge in Metabolite Identification
Untargeted LC/MS experiments generate extensive data, but:
- Most workflows rely on qualitative MSI levels without statistical confidence
- Isomeric compounds lead to ambiguous identifications
- Strict filtering limits analysis to a small subset of metabolites
- Pathway analysis is constrained by incomplete or uncertain
As a result, valuable metabolic signals are excluded from biological interpretation.
MassID removes these roadblocks with an end-to-end identification workflow built for scale, rigor and confidence.
The MassID Approach
- AI-driven peak detection and noise filtering
- Probabilistic metabolite identification engine
- Full false discovery rate (FDR) control for transparent filtering
- Integration of MS1, MS/MS and retention time information
This unified approach replaces subjective MSI labels with quantitative confidence scores that can be traced, turned and trusted.
Broad Chemical Space Coverage
MassID evaluates every detected signal against a reference database of more than 280,000 compounds, enriched with experimental and predicted retention times. This broad foundation supports also confident identification of endogenous and environmental metabolites alike, without being limited by small targeted panels or narrow standard libraries.
Application: Human Plasma Metabolomics comparing Healthy and Cardiovascular Disease Patients
When applied to human plasma using Panome Bio’s Next-Generation Metabolomics® platform with MassID:
- Over 195,000 features were detected across four LC/MS assays
- More than 99.9% of features were confidently classified or removed as noise
- Over 4,500 metabolites were structurally identified
- More than 1,200 metabolites met a stringent 5% FDR threshold
Instead of restricting analysis to MSI Level 1 and 2 compounds, MassID™ enables probability‑weighted inclusion of thousands of metabolites, unlocking far richer biology from every dataset.
Next-Level Metabolic Profiling
Pathway analysis expanded from 63 pathways (MSI L1/L2 only) to 193 pathways, more than threefold increase. This delivers a richer, systems-level view of metabolic networks that would remain invisible under MSI workflow.
Beyond Data Quality And Scale
MassID demonstrates strong technical reproducibility, with a median technical coefficient of variation (CV) of 3.4%, alongside broad biological diversity across samples (median CV = 47.1%).
These results demonstrate how confidence-based identification supports biologically meaningful conclusions.
A Five-Fold Leap in Pathway Coverage
The impact of MassID becomes most evident at the pathway level. Using strict MSI Level 1/2 filtering, only five pathways showed significant enrichment. With MassID, up to 25 significantly altered pathways were identified in Cardio Vascular Disease. These patterns are revealing lipid and mitochondrial changes invisible to conventional workflows.
This enables pathway-level interpretation without sacrificing rigor.
Why MassID
- Probability-based metabolite identification
- Full FDR control
- Broad chemical space coverage
- Designed for large-scale, untargeted studies
MassID transforms untargeted metabolomics data into a reliable foundation for downstream analysis.
Advancing Untargeted Metabolomics Data Analysis with MassID™
Dive into our Whitepaper including more details and highlights.
MassID provides near complete annotation of metabolomics data with identification probabilities
Dive into the full scientific publication including more details
MassID™: Turning Untargeted Data into Confident Discoveries
Learn in this brochure how MassID enhances Next-Generation Metabolomics® expanding metabolite identification and pathway coverage.
Don’t limit discovery to small libraries.
Analyze your samples with Panome Bio’s Next-Generation Metabolomics using MassID. Evaluate thousands of detected signals against a broad metabolite database, with confidence scores that support downstream analysis.